Trial Profile
A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 2.5%, 5.0%, and 7.5% Solutions vs. Vehicle for the Treatment of Adult Subjects With Onychomycosis of the Great Toenail
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2018
Price :
$35
*
At a glance
- Drugs Tavaborole (Primary)
- Indications Onychomycosis
- Focus Therapeutic Use
- Sponsors Anacor Pharmaceuticals
- 20 May 2014 New trial record